Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries

BMC Infectious Diseases

Table 4 Result data from first 12 months of Xpert MTB/RIF implementation in nine countries

Xpert site	Tests	MTB Positive		Rifampicin						Failed Tests		Type of failed test						MTB + w/o failed tests
		N	%	Sensitive		Indeterminate		Resistant		n	%	Error		Invalid		No result		MTB + w/o failed tests
				n	%	N	%	n	%			N	%	n	%	n	%
Bangladesh	1428	286	20.0%	249	87.1%	11	3.8%	26	9.1%	99	6.9%	85	85.9%	10	10.1%	4	4.0%	21.5%
Cambodia	3697	768	20.8%	741	96.5%	22	2.9%	5	0.7%	439	11.9%	169	38.5%	264	60.1%	6	1.4%	23.6%
DR Congo	6348	567	8.9%	498	87.8%	17	3.0%	30	5.3%	1032	16.3%	868	84.1%	107	10.4%	57	5.5%	10.7%
Kenya	2803	258	9.2%	238	92.2%	11	4.3%	9	3.5%	266	9.5%	240	90.2%	23	8.6%	3	1.1%	10.2%
Malawi	6258	632	10.1%	602	93.5%	9	1.4%	21	3.3%	853	13.6%	546	64.0%	265	31.1%	42	4.9%	11.7%
Moldova	11472	1965	17.1%	1227	62.4%	48	2.4%	690	35.1%	673	5.9%	387	61.7%	105	15.6%	181	26.9%	18.2%
Mozambique	6823	910	13.3%	826	90.8%	18	2.0%	66	7.3%	871	12.8%	521	59.8%	216	24.8%	134	15.4%	15.3%
Nepal	6943	1376	19.8%	1257	91.4%	14	1.0%	105	7.6%	744	10.7%	409	55.0%	148	19.9%	187	25.1%	22.2%
Pakistan	2201	433	19.7%	390	90.1%	13	3.0%	30	6.9%	130	5.9%	77	59.2%	37	28.5%	16	12.3%	20.9%
All Countries	47973	7195	15.0%	6028	83.8%	163	2.3%	982	13.6%	5107	10.6%	3302	64.7%	1175	23.0%	630	12.3%	16.8%
South Africa ^a	1180669	171792	14.6%	155811	90.7%	2443	1.4%	12266	7.1%	32561	2.8%							15.0%

^aReference 26. Data for South Africa is presented as a comparison after 25 months of implementation.

ISSN: 1471-2334